Medical News

RSS

Xenex Healthcare Services announces commercial launch of pulsed xenon room disinfection system

Xenex Healthcare Services LLC, which specializes in developing disinfection technology for healthcare facilities, today announced the commercial launch of its pulsed xenon room disinfection system and the conclusion of the Xenex system's successful trial at a leading U.S. cancer center. The Xenex system, which is now available, is the fastest, safest, and most effective method for the advanced cleaning of hospital rooms in the world today, quickly destroying all major classes of microorganisms (including viruses, bacteria and bacterial spores) without contact or chemicals.

8 Jun 2010

GTx reports positive results from toremifene Phase III clinical trial

GTx, Inc. announced today that in the Phase III clinical trial evaluating toremifene 80 mg for the reduction of fractures and treatment of other estrogen deficiency side effects in men with prostate cancer on androgen deprivation therapy (ADT), toremifene treatment demonstrated an improved benefit/risk ratio in men less than 80 years of age. The data were presented yesterday at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.

8 Jun 2010

CMAJ to publish comprehensive new guidelines on immigrant health

CMAJ will publish a ground-breaking series of comprehensive new guidelines on immigrant health (pre-embargo link only) beginning June 7, 2010 . The Canadian Immigrant Health Guidelines, a multi-part series, will assist clinicians, policy makers and immigrants in understanding the diverse needs of immigrants to Canada. Few resources like this exist in the international medical literature.

8 Jun 2010

ZixCorp announces new, 3-year email encryption contract with Orlando Health

Zix Corporation, the leader in email encryption services, has announced a new, three-year contract with Orlando Health, a $1.5 billion not-for-profit health care organization and a community-based network of hospitals and care centers in the Orlando region.

8 Jun 2010

NYBA recognizes Acorda Therapeutics President with The Cures Start Here Business Leader of the Year Award

Acorda Therapeutics, Inc. today announced that Ron Cohen, M.D., President and Chief Executive Officer, is the recipient of the New York Biotechnology Association "The Cures Start Here" Business Leader of the Year Award. The award is presented for outstanding service to the patient community and to NYBA.

8 Jun 2010

SciMed Technologies receives certification for VitaKit A from AOAC International

SciMed Technologies Inc. today announces they received certification from the AOAC International - a worldwide scientific association dedicated to analytical excellence - for VitaKit A the world's first 2 hour rapid test for accurate analysis of vitamin A in liquid milk.

8 Jun 2010

U.S. Court issues claim construction order in patent infringement litigation between Cubist and Teva

Cubist Pharmaceuticals, Inc. today announced that the U.S. District Court for the District of Delaware issued a claim construction order in the litigation between Cubist and Teva.

8 Jun 2010

Springhill retirement community opens Woodlands Memory Support Neighborhood

Families with loved ones who have memory challenges will breathe a sigh of relief on June 11, when Springhill retirement community opens the doors to the Woodlands Memory Support Neighborhood. A presentation by Springhill Executive Director Jim Schneider and Ed Thomas, CEO of Asbury Communities, the management company for Springhill, will begin at 11:00 a.m. with tours of the new neighborhood to follow.

8 Jun 2010

Idera reports preliminary results from IMO-3100 Phase 1 clinical trial for autoimmune, inflammatory diseases

Idera Pharmaceuticals, Inc. today announced preliminary results from a Phase 1 clinical trial of IMO-3100, its lead Toll-like Receptor (TLR) 7 and TLR9 antagonist drug candidate for potential applications in autoimmune and inflammatory diseases. In this trial, healthy subjects in five dosage cohorts received single doses of IMO-3100 from 0.04 to 0.64 mg/kg. IMO-3100 was well tolerated at all dose levels.

8 Jun 2010

RealMed signs multi-year agreement with MED3OOO

RealMed Corporation, a leading provider of web-based revenue cycle management solutions for healthcare providers, hospitals, and payers, today announced a multi-year agreement with MED3OOO, a national leader in providing advanced healthcare management and technologies to physicians. RealMed will provide secure, Internet-based, real-time adjudication and processing of electronic claims transactions, real-time claims editing, automatic claims status and electronic remittance advice management.

8 Jun 2010

QOI selects multi-tenant SaaS CRM system from Veeva System

QLT Ophthalmics, Inc., a wholly-owned U.S. subsidiary of QLT Inc., selected Veeva System's multi-tenant SaaS CRM system built on the cloud computing model. QOI was formed by QLT Inc. in Q4 2009 to take over the sales and marketing of Visudyne in the U.S. from Novartis Pharma AG.

8 Jun 2010

Protalix BioTherapeutics reports positive results from PRX-105 Phase I clinical trial

Protalix BioTherapeutics, Inc. announced today the completion of its phase I clinical trial of PRX-105, a plant cell expressed pegylated recombinant human acetylcholinesterase in development for biodefense indications. The trial established the pharmacokinetics of the protein and demonstrated that single dose, intravenous administration of PRX-105 is safe and well tolerated.

8 Jun 2010

Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010

VIVUS, Inc. today announced that data from a previously reported phase 2 study evaluating the safety and efficacy of the investigational drug Qnexa for the treatment of obstructive sleep apnea were presented at SLEEP 2010, the 24th Annual Meeting of the Associated Professional Sleep Societies.

8 Jun 2010

FDA grants Cepheid marketing clearance for Xpert SA Nasal Complete molecular test

Cepheid today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert® SA Nasal Complete, the first and only molecular test designed for the simultaneous detection and differentiation of both Staphylococcus aureus (SA) and Methicillin-resistant Staphylococcus aureus (MRSA) colonization in less than one hour. The test runs on Cepheid's GeneXpert® System, the world's leading molecular platform for accuracy, speed, and ease-of-use.

8 Jun 2010

Patient Home Monitoring to trade under ticker symbol "PHM" on TSX Venture Exchange

Patient Home Monitoring, a company focused on in-home cardiology healthcare services, today announced that it will begin trading under the ticker symbol "PHM" on the TSX Venture Exchange at the open of market today, Tuesday, June 8, 2010.

8 Jun 2010

New technique to prevent tumours developing in connection with stem cell transplantations

Researchers at Lund University have come up with a new technique to prevent tumours developing in connection with stem cell transplantations. The results have been published today in the respected scientific journal PNAS.

8 Jun 2010

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

Salix Pharmaceuticals, Ltd. today announced that the Company has submitted an efficacy supplement to NDA 21-361 for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating.

8 Jun 2010

$UC-MSCT improves symptoms, biochemical values in patients with severe refractory SLE: Study$

UC-MSCT improves symptoms, biochemical values in patients with severe refractory SLE: Study

A new study shows that umbilical cord mesenchymal stem cell transplant may improve symptoms and biochemical values in patients with severe refractory systemic lupus erythematosus.

8 Jun 2010

Columbia completes enrollment in PROCHIEVE 8% Phase III study to reduce preterm birth in short cervix women

Columbia Laboratories, Inc. today announced it completed enrollment in the PREGNANT (PROCHIEVE Extending GestatioN A New Therapy) Study last week. This randomized, double-blind, placebo controlled Phase III clinical study is evaluating the safety and efficacy of PROCHIEVE® 8% (progesterone gel) to reduce the risk of preterm birth in women with a cervical length between 1.0 and 2.0 centimeters as measured by transvaginal ultrasound at mid-pregnancy.

8 Jun 2010

USPTO grants ISCO patent to International Stem Cell's hpSC

International Stem Cell Corporation, www.intlstemcell.com, announced today that the United States Patent and Trademark Office has granted ISCO patent number 7,732,202, the first of several pending patents relating to its development of human parthenogenetic Stem Cells. Human parthenogenetic stem cells are a new type of pluripotent stem cell that allows immune matching to potentially solve critical immune rejection problems, and does not involve the ethical issues that surround the use of fertilized human embryos.

8 Jun 2010

Medical News

Xenex Healthcare Services announces commercial launch of pulsed xenon room disinfection system

GTx reports positive results from toremifene Phase III clinical trial

CMAJ to publish comprehensive new guidelines on immigrant health

ZixCorp announces new, 3-year email encryption contract with Orlando Health

NYBA recognizes Acorda Therapeutics President with The Cures Start Here Business Leader of the Year Award

SciMed Technologies receives certification for VitaKit A from AOAC International

U.S. Court issues claim construction order in patent infringement litigation between Cubist and Teva

Springhill retirement community opens Woodlands Memory Support Neighborhood

Idera reports preliminary results from IMO-3100 Phase 1 clinical trial for autoimmune, inflammatory diseases

RealMed signs multi-year agreement with MED3OOO

QOI selects multi-tenant SaaS CRM system from Veeva System

Protalix BioTherapeutics reports positive results from PRX-105 Phase I clinical trial

Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010

FDA grants Cepheid marketing clearance for Xpert SA Nasal Complete molecular test

Patient Home Monitoring to trade under ticker symbol "PHM" on TSX Venture Exchange

New technique to prevent tumours developing in connection with stem cell transplantations

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

UC-MSCT improves symptoms, biochemical values in patients with severe refractory SLE: Study

Columbia completes enrollment in PROCHIEVE 8% Phase III study to reduce preterm birth in short cervix women

USPTO grants ISCO patent to International Stem Cell's hpSC

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News